Second-line chemotherapy has been proved to be effective on @entity1 with relapsed or @entity151 ( @entity151 ). Although @entity1945 has been approved by many countries for the monotherapy with an acknowledged efficacy, its efficacy of low response rate and short median survival time is disappointing. Considering the optimal regimen of second-line therapy is yet uncertain, we conducted this meta-analysis to provide theoretical basis for making clinical decisions. A comprehensive electronic search was performed to identify eligible studies. The ending points included response, overall survival (OS), and adverse events. Odds ratios and 95% confidence interval were calculated to compare the effects. Six trials with 1369 @entity1 were included. With regard to response rate, only @entity12418 showed a significant improvement compared with @entity1945 . @entity2600 and @entity2879 did not show any advantages. When targeted on OS, neither of these monotherapy regimens exhibited any advantage when compared to @entity1945 . When aimed at @entity137 , @entity12418 showed a better effect on reducing hematologic @entity137 , but a worse outcome on increasing the nonhematologic @entity137 , whereas others showed equal efficacy. There is no strong evidence that any advantage for second-line treatment of @entity151 when compared with @entity1945 , except @entity12418 . And @entity12418 seems to be superior to @entity1945 in terms of response rates, with a lower @entity137 than @entity1945 , which is of high value in clinical application, and may be the direction of second-line monotherapy in the future.

Efficacy of different monotherapies in second-line treatment for XXXX : a meta-analysis of randomized controlled trials.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity12418 :: ('MESH:C055866', 'Chemical') :: ['amrubicin'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity'] @entity2600 :: ('MESH:C051890', 'Chemical') :: ['Irinotecan'] @entity2879 :: ('MESH:D005047', 'Chemical') :: ['etoposide'] @entity151 :: ('MESH:D055752', 'Disease') :: ['refractory small cell lung cancer', 'SCLC'] @entity1945 :: ('MESH:D019772', 'Chemical') :: ['topotecan']
@entity151 :: (MESH:D055752,Disease) :: ['small cell lung cancer']
